Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Maintenance strategies for relapse prevention and treatment.Hematology. American Society of Hematology. Education Program · 2024
   Review
2. Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure.Cancers · 2022
   Review
3. [Regulatory effect of molecular targeted drugs on the immune system for liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
   Review
4. Peptides, Antibodies, Peptide Antibodies and More.International journal of molecular sciences · 2019
   Review
5. Allogeneic transplant forTherapeutic advances in hematology · 2019
   Review

Corrections and comments

• Erratum for
  Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.2018

Authors and funding

130 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract